NEW YORK (GenomeWeb) – Cell-and bead-based screening technologies firm IntelliCyt has closed a $2.5 million secured term loan agreement and a $1.5 million revolving line of credit from Oxford Finance, the financing firm announced today.

Albuquerque, NM-based IntelliCyt will use the debt facility for working capital, as well as product development and marketing. The company develops high-throughput, high-content screening products for phenotypic drug discovery, antibody discovery, and in vivo toxicity testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.